Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Rituximab 1402Cyclophosphamide 1308Vincristine 670Doxorubicin 589Etoposide 527Prednisone 512Cytarabine 487fludarabine 470Methotrexate 446Dexamethasone 414fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 283Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 164Magnetic Resonance Spectroscopy 157Calcium Dobesilate 151

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
MAC-ST-001 × Lymphoid × Clear all
NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡